GICS Sector : Healthcare
Harvard Bioscience, Inc.develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally.The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments.
Harvard Bioscience reported third-quarter revenue of $20.6 million, at the high end of its guidance range, representing a slight sequential increase. Gross margin expanded to 58.4%, exceeding the company's guidance range and improving sequentially from 56.4% in the second quarter. Adjusted EBITDA increased to $2 million, up from $1.3 million in the same period last year. However, the company's EPS came in at -$0.01, missing estimates of $0.04.
Publication Date: Nov -19
The company's revenue growth was driven by a broad uptick in demand for its telemetry products across different regions and customer groups, as noted by John Duke, "We benefited from a broad uptick in demand for our telemetry products, and it was not just in one region, it was across regions as well as different customer groups." This growth was reflected in the company's preclinical systems, which saw an increase in demand.
The company's backlog stood at its highest level in two years, driven by the launch of new products. Mark Frost noted that the improved backlog was not driven by one specific product or region, but rather a broad-based improvement across the company's product portfolio. For the fourth quarter, the company guided to revenue in the range of $22.5 million to $24.5 million, potentially resulting in flat revenue at the high end of the range. Analysts estimate revenue growth of 7.2% for next year.
With a P/S Ratio of 0.32 and an EV/EBITDA of -1.38, the company's valuation multiples suggest a relatively low expectation for growth and profitability. The company's current valuation is also reflected in its P/E Ratio of -0.49 and P/B Ratio of 1.8. The Free Cash Flow Yield is 17.24%, indicating a potential opportunity for investors. However, the ROE and ROIC are significantly negative, at -144.21% and -68.79%, respectively, highlighting the challenges the company still faces in terms of profitability.
Harvard Bioscience (NASDAQ:HBIO) Stock Crosses Above 200-Day Moving Average – Here’s What Happened
Dec -03
Jeffrey Epstein files: Larry Summers steps back from public commitments over email fallout
Nov -18
Harvard Bioscience, Inc. (HBIO) Q3 2025 Earnings Call Transcript
Nov -07
Harvard Bioscience Announces Third Quarter 2025 Financial Results
Nov -06
Harvard Bioscience Schedules Third Quarter 2025 Earnings Conference Call for November 6, 2025 at 8:00 AM ET
Oct -30
Harvard Bioscience Expands Distribution Agreement with Fisher Scientific to Include United States
Sep -16
Harvard Bioscience Announces Appointment of Stephen DeNelsky to Board of Directors
Sep -09
Harvard Bioscience, Inc. (HBIO) Q2 2025 Earnings Call Transcript
Aug -11
Growing demand for life science research, increasing adoption of novel technologies, and rising investments in biotechnology and pharmaceutical industries drive the growth of Harvard Bioscience's products.
Growing demand for life science research equipment, increasing need for extended support and maintenance, and rising adoption of preventive maintenance practices drive the growth of Harvard Bioscience's service contracts.
A comprehensive software platform for data acquisition, analysis, and visualization of physiological signals
A range of instruments and systems for behavioral and physiological research, including fear conditioning, anxiety, and social behavior
A line of electroporation instruments for in vitro and in vivo gene delivery and molecular biology research
A range of molecular biology and genomics instruments, including thermal cyclers, sequencers, and microarray scanners
A range of instruments for physiological research, including ventilators, anesthesia systems, and surgical instruments
Harvard Bioscience, Inc. operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the availability of alternative products and services.
Harvard Bioscience, Inc. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are specialized, making it difficult for customers to switch to alternative suppliers.
Harvard Bioscience, Inc. relies on a few key suppliers for critical components, which gives them some bargaining power. However, the company's diversified supply chain and long-term contracts mitigate this risk.
The biotechnology industry has high barriers to entry, including significant capital requirements, regulatory hurdles, and the need for specialized expertise. This makes it difficult for new entrants to compete with established players like Harvard Bioscience, Inc.
The biotechnology industry is highly competitive, with many established players competing for market share. Harvard Bioscience, Inc. faces intense competition from companies like Thermo Fisher Scientific, Danaher, and PerkinElmer.
| Value | |
|---|---|
| Debt Weight | 34.20% |
| Debt Cost | 6.28% |
| Equity Weight | 65.80% |
| Equity Cost | 11.25% |
| WACC | 9.55% |
| Leverage | 51.97% |
Value: 4.6
Growth: 5.7
Quality: 5.7
Yield: 0.0
Momentum: 8.5
Volatility: 3.0
1-Year Total Return ->
Value: 3.5
Growth: 3.0
Quality: 6.2
Yield: 1.0
Momentum: 5.0
Volatility: 2.0
1-Year Total Return ->
Value: 7.4
Growth: 4.9
Quality: 4.2
Yield: 0.0
Momentum: 1.5
Volatility: 1.7
1-Year Total Return ->
Value: 6.0
Growth: 2.8
Quality: 3.1
Yield: 0.0
Momentum: 4.0
Volatility: 0.3
1-Year Total Return ->
Value: 6.6
Growth: 3.2
Quality: 4.3
Yield: 0.0
Momentum: 0.0
Volatility: 1.0
1-Year Total Return ->
Value: 9.2
Growth: 1.1
Quality: 2.6
Yield: 0.0
Momentum: 0.0
Volatility: 0.0
1-Year Total Return ->